title: The conservative treatment of myasthenia gravis.
abstract: Neostigmine is at present the mainstay in treatment of myasthenia gravis. Adjuvant therapy with ephedrine, potassium chloride, or guanidine is recommended. Urecholine,(R) also used as an adjuvant, is still in the experimental stage and should only be given by one acquainted with its properties and toxic effects. Di-isopropylfluorophosphate and tetraethyl pyrophosphate likewise are still in the experimental stage. Since they are extremely toxic and unstable, general use of them is discouraged until further experimental and therapeutic studies are completed. The results of thymectomy and radiation of the thymus are equivocal and these procedures should be reserved for severe cases which should be selected only after a thorough study.
authors.forename: R B
authors.initials: RB
authors.lastname: AIRD
authors.forename: M B
authors.initials: MB
authors.lastname: CAMPBELL
mesh_terms: D003131:Combined Modality Therapy; D004809:Ephedrine; D006801:Humans; D009157:Myasthenia Gravis; D009388:Neostigmine; D013934:Thymectomy
chemical_list: D009388:Neostigmine; D004809:Ephedrine